Research progress on the efficacy and safety of PARP inhibitors in mCRPC
10.3760/cma.j.cn112330-20221121-00623
- VernacularTitle:PARP抑制剂在mCRPC中疗效和安全性的研究进展
- Author:
Hao LIU
1
;
Pengtao TANG
;
Jian HUANG
Author Information
1. 中山大学孙逸仙纪念医院泌尿外科，广州 510120
- Keywords:
Prostatic neoplasms;
Carcinoma;
Metastatic;
Castration-resistant;
Poly ADP-ribose polymerase inhibitors;
Efficacy;
Safety
- From:
Chinese Journal of Urology
2023;44(7):551-554
- CountryChina
- Language:Chinese
-
Abstract:
Poly ADP-ribose polymerase (PARP) inhibitors are novel agents for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in recent years, and a variety of PARP inhibitors have been reported with clinical evidence for the beneficial. Although these drugs are actually of attributes with pharmacological similarities, due to the discrepancies in the molecular structure and pharmacodynamics, the respective efficacy and safety from clinical circumstances are quite varied. While it comes to the best clinical determination, the optimization for regimen is important on the basis of clinical exhaustiveness for the reports, in addition the laboratory examination for mCRPC, and either the tumorous genetic benchmark are necessarily being calculated.
